{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:29Z","timestamp":1783632929646,"version":"3.55.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11102-022-01212-4","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T19:04:55Z","timestamp":1647543895000},"page":"383-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeted therapies in the medical management of craniopharyngioma"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1985","authenticated-orcid":false,"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"1212_CR1","doi-asserted-by":"crossref","unstructured":"Muller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S (2019) Craniopharyngioma. Nat Rev Dis Primers 5:75-019-0125-9","DOI":"10.1038\/s41572-019-0125-9"},{"key":"1212_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00381-004-1124-y","volume":"21","author":"HL M\u00fcller","year":"2005","unstructured":"M\u00fcller HL, Bruhnken G, Emser A, Faldum A, Etavard-Gorris N, Gebhardt U, Kolb R, S\u00f6rensen N (2005) Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst 21:975\u2013980","journal-title":"Childs Nerv Syst"},{"key":"1212_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11060-011-0540-6","volume":"104","author":"EH Nielsen","year":"2011","unstructured":"Nielsen EH, Feldt-Rasmussen U, Poulsgaard L, Kristensen LO, Astrup J, Jorgensen JO, Bjerre P, Andersen M, Andersen C, Jorgensen J, Lindholm J, Laurberg P (2011) Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults. J Neurooncol 104:755\u2013763","journal-title":"J Neurooncol"},{"key":"1212_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/neuonc\/nos142","volume":"14","author":"BE Zacharia","year":"2012","unstructured":"Zacharia BE, Bruce SS, Goldstein H, Malone HR, Neugut AI, Bruce JN (2012) Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro Oncol 14:1070\u20131078","journal-title":"Neuro Oncol"},{"key":"1212_CR5","doi-asserted-by":"crossref","unstructured":"Zucchini S, Di Iorgi N, Pozzobon G, Pedicelli S, Parpagnoli M, Driul D, Matarazzo P, Baronio F, Crocco M, Giudica G, Partenope C, Nardini B, Ubertini G, Menardi R, Guzzetti C, Iughetti L, Aversa T, Di Mase R, Cassio A, Cianfarani S, Maghnie M, Tuli G, Loche S, Bruzzi P, Wasniewska M, Salerno M, Rutigliano I, Iezzi ML, Cherubini V, Grandone A, Faienza M, Tumini S, Baldoli C, Consales A, Genitori L, Marras CE, MIlanaccio C, Mortini P, Vindigni M, Zenga F, Zucchelli M Physiopathology of Growth Processes, Puberty Study Group of the Italian Society for Pediatric Endocrinology and Diabetology (2022) Management of childhood-onset craniopharyngioma in Italy: A multicenter seven year follow-up study of 145 patients. J Clin Endocrinol Metab 107:e1020\u2013e1031","DOI":"10.1210\/clinem\/dgab784"},{"key":"1212_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fendo.2012.00039","volume":"3","author":"U Bartels","year":"2012","unstructured":"Bartels U, Laperriere N, Bouffet E, Drake J (2012) Intracystic therapies for cystic craniopharyngioma in childhood. Front Endocrinol (Lausanne) 3:39","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1212_CR7","first-page":"CD008890","volume":"7","author":"S Zhang","year":"2016","unstructured":"Zhang S, Fang Y, Cai BW, Xu JG, You C (2016) Intracystic bleomycin for cystic craniopharyngiomas in children. Cochrane Database Syst Rev 7:CD008890","journal-title":"Cochrane Database Syst Rev"},{"key":"1212_CR8","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1016\/j.wneu.2019.07.217","volume":"132","author":"F Frio","year":"2019","unstructured":"Frio F, Solari D, Cavallo LM, Cappabianca P, Raverot G, Jouanneau E (2019) Ommaya Reservoir System for the Treatment of Cystic Craniopharyngiomas: Surgical Results in a Series of 11 Adult Patients and Review of the Literature. World Neurosurg 132:e869\u2013e877","journal-title":"World Neurosurg"},{"key":"1212_CR9","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2018.3.FOCUS1861","volume":"44","author":"S Gupta","year":"2018","unstructured":"Gupta S, Bi WL, Giantini Larsen A, Al-Abdulmohsen S, Abedalthagafi M, Dunn IF (2018) Craniopharyngioma: a roadmap for scientific translation. Neurosurg Focus 44:E12","journal-title":"Neurosurg Focus"},{"key":"1212_CR10","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.1210\/jc.2019-01299","volume":"104","author":"KI Alexandraki","year":"2019","unstructured":"Alexandraki KI, Kaltsas GA, Karavitaki N, Grossman AB (2019) The Medical Therapy of Craniopharyngiomas: The Way Ahead. J Clin Endocrinol Metab 104:5751\u20135764","journal-title":"J Clin Endocrinol Metab"},{"key":"1212_CR11","doi-asserted-by":"crossref","unstructured":"Rostami E, Casar-Borota O, Gudjonsson O (2020) Molecular Targets in Craniopharyngioma. In: Jouanneau E, Raverot G (eds) Adult Craniopharyngiomas. Springer Nature Switzerland AG, pp 209\u2013218","DOI":"10.1007\/978-3-030-41176-3_12"},{"key":"1212_CR12","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/2019.10.FOCUS19705","volume":"48","author":"AC Hengartner","year":"2020","unstructured":"Hengartner AC, Prince E, Vijmasi T, Hankinson TC (2020) Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurg Focus 48:E7","journal-title":"Neurosurg Focus"},{"key":"1212_CR13","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00381-020-04677-5","volume":"36","author":"R Whelan","year":"2020","unstructured":"Whelan R, Hengartner A, Folzenlogen Z, Prince E, Hankinson TC (2020) Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review. Childs Nerv Syst 36:1635\u20131642","journal-title":"Childs Nerv Syst"},{"key":"1212_CR14","doi-asserted-by":"crossref","unstructured":"Apps JR, Martinez-Barbera JP (2021) Pathophysiology and genetics in craniopharyngioma. In: Honegger J, Reincke M, Petersenn S (eds) Pituitary Tumors. Academic Press, pp 53\u201366","DOI":"10.1016\/B978-0-12-819949-7.00020-2"},{"key":"1212_CR15","doi-asserted-by":"publisher","first-page":"bvab094","DOI":"10.1210\/jendso\/bvab094","volume":"5","author":"HW Gan","year":"2021","unstructured":"Gan HW (2021) Management of Craniopharyngiomas in the Era of Molecular Oncological Therapies: Not a Panacea. J Endocr Soc 5:bvab094","journal-title":"J Endocr Soc"},{"key":"1212_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3171\/jns.1995.83.2.0206","volume":"83","author":"TB Crotty","year":"1995","unstructured":"Crotty TB, Scheithauer BW, Young WF Jr, Davis DH, Shaw EG, Miller GM, Burger PC (1995) Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 83:206\u2013214","journal-title":"J Neurosurg"},{"key":"1212_CR17","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/S0002-9440(10)64477-X","volume":"161","author":"S Sekine","year":"2002","unstructured":"Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M, Hirohashi S (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997\u20132001","journal-title":"Am J Pathol"},{"key":"1212_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HG, Taha H, Martinez-Lage M, Santi M, Storm PB, Lee JY, Palmer JN, Adappa ND, Scott RM, Dunn IF, Laws ER Jr, Stewart C, Ligon KL, Hoang MP, Van Hummelen P, Hahn WC, Louis DN, Resnick AC, Kieran MW, Getz G, Santagata S (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46:161\u2013165","journal-title":"Nat Genet"},{"key":"1212_CR19","doi-asserted-by":"publisher","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","volume":"108","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT Jr (2015) Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst 108:djv310 Barker FG,2nd. doi: https:\/\/doi.org\/10.1093\/jnci\/djv310","journal-title":"J Natl Cancer Inst"},{"key":"1212_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","volume":"19","author":"SJ Aylwin","year":"2016","unstructured":"Aylwin SJ, Bodi I, Beaney R (2016) Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 19:544\u2013546","journal-title":"Pituitary"},{"key":"1212_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/cns-2016-0034","volume":"6","author":"A Roque","year":"2017","unstructured":"Roque A, Odia Y (2017) BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol 6:95\u201399","journal-title":"CNS Oncol"},{"key":"1212_CR22","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","volume":"159","author":"E Rostami","year":"2017","unstructured":"Rostami E, Witt Nystr\u00f6m P, Libard S, Wikstr\u00f6m J, Casar-Borota O, Gudjonsson O (2017) Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir (Wien) 159:2217\u20132221","journal-title":"Acta Neurochir (Wien)"},{"key":"1212_CR23","doi-asserted-by":"crossref","unstructured":"Himes BT, Ruff MW, Van Gompel JJ, Park SS, Galanis E, Kaufmann TJ, Uhm JH (2018) Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report.J Neurosurg:1\u20135","DOI":"10.3171\/2017.11.JNS172373"},{"key":"1212_CR24","doi-asserted-by":"crossref","unstructured":"Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, Rostami E, Gudjonsson O, Shaw BL, Cahill DP, Galanis E, Barker FG 2, Santagata S, Brastianos PK (2019) Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 125:2910\u20132914","DOI":"10.1002\/cncr.32197"},{"key":"1212_CR25","doi-asserted-by":"crossref","unstructured":"Bernstein A, Mrowczynski OD, Greene A, Ryan S, Chung C, Zacharia BE, Glantz M (2019) Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.J Neurosurg:1\u20136","DOI":"10.3171\/2019.8.JNS19643"},{"key":"1212_CR26","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.18632\/oncotarget.27203","volume":"10","author":"M Rao","year":"2019","unstructured":"Rao M, Bhattacharjee M, Shepard S, Hsu S (2019) Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget 10:6038\u20136042","journal-title":"Oncotarget"},{"key":"1212_CR27","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","volume":"18","author":"K Khaddour","year":"2020","unstructured":"Khaddour K, Chicoine MR, Huang J, Dahiya S, Ansstas G (2020) Successful Use of BRAF\/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma. J Natl Compr Canc Netw 18:1590\u20131595","journal-title":"J Natl Compr Canc Netw"},{"key":"1212_CR28","doi-asserted-by":"publisher","first-page":"vdaa141","DOI":"10.1093\/noajnl\/vdaa141","volume":"2","author":"AL Di Stefano","year":"2020","unstructured":"Di Stefano AL, Guyon D, Sejean K, Feuvret L, Villa C, Berzero G, Desforges Bullet V, Halimi E, Boulin A, Baussart B, Gaillard S (2020) Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. Neurooncol Adv 2:vdaa141. doi: https:\/\/doi.org\/10.1093\/noajnl\/vdaa141","journal-title":"Neurooncol Adv"},{"key":"1212_CR29","doi-asserted-by":"publisher","first-page":"bvab043","DOI":"10.1210\/jendso\/bvab043","volume":"5","author":"CL Chik","year":"2021","unstructured":"Chik CL, van Landeghem FKH, Easaw JC, Mehta V (2021) Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor. J Endocr Soc 5:bvab043. doi: https:\/\/doi.org\/10.1210\/jendso\/bvab043","journal-title":"J Endocr Soc"},{"key":"1212_CR30","doi-asserted-by":"publisher","unstructured":"Brastianos P, Kaliopi T, Erin GS, Michelle GE, Robins, Kaufmann TJ, Bota D, Annenelie, Reardon DA, Cohen A, De La Louis M, Ines LG, Jay CJ, Cahill DP, Shih H, Alice, Brown PD, Barker FG Galanis, Evanthia (2021) Alliance A071601: Phase II trial of BRAF\/MEK inhibition in newly diagnosed papillary craniopharyngiomas. Journal of Clinical Oncology 39:2000\u20132000. doi: https:\/\/doi.org\/10.1200\/jco.2021.39.15_suppl.2000","DOI":"10.1200\/jco.2021.39.15_suppl.2000"},{"key":"1212_CR31","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2010.1.FOCUS09310","volume":"28","author":"S Cavalheiro","year":"2010","unstructured":"Cavalheiro S, Di Rocco C, Valenzuela S, Dastoli PA, Tamburrini G, Massimi L, Nicacio JM, Faquini IV, Ierardi DF, Silva NS, Pettorini BL, Toledo SR (2010) Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus 28:E12","journal-title":"Neurosurg Focus"},{"key":"1212_CR32","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3171\/2010.1.FOCUS09315","volume":"28","author":"P Steinbok","year":"2010","unstructured":"Steinbok P, Hukin J (2010) Intracystic treatments for craniopharyngioma. Neurosurg Focus 28:E13","journal-title":"Neurosurg Focus"},{"key":"1212_CR33","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1158\/1078-0432.CCR-10-2811","volume":"17","author":"A H\u00f6lsken","year":"2011","unstructured":"H\u00f6lsken A, Gebhardt M, Buchfelder M, Fahlbusch R, Bl\u00fcmcke I, Buslei R (2011) EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res 17:4367\u20134377","journal-title":"Clin Cancer Res"},{"key":"1212_CR34","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.3171\/2016.9.FOCUS16316","volume":"41","author":"C Stache","year":"2016","unstructured":"Stache C, Bils C, Fahlbusch R, Flitsch J, Buchfelder M, Stefanits H, Czech T, Gaipl U, Frey B, Buslei R, H\u00f6lsken A (2016) Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin. Neurosurg Focus 41:E14","journal-title":"Neurosurg Focus"},{"key":"1212_CR35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, Manshaei S, Jani N, H\u00f6lsken A, Pettorini B, Beynon RJ, Simpson DM, Fraser HC, Hong Y, Hallang S, Stone TJ, Virasami A, Donson AM, Jones D, Aquilina K, Spoudeas H, Joshi AR, Grundy R, Storer LCD, Korbonits M, Hilton DA, Tossell K, Thavaraj S, Ungless MA, Gil J, Buslei R, Hankinson T, Hargrave D, Goding C, Andoniadou CL, Brogan P, Jacques TS, Williams HJ, Martinez-Barbera JP (2018) Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol 135:757\u2013777","journal-title":"Acta Neuropathol"},{"key":"1212_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3389\/fonc.2019.00791","volume":"9","author":"S Grob","year":"2019","unstructured":"Grob S, Mirsky DM, Donson AM, Dahl N, Foreman NK, Hoffman LM, Hankinson TC, Mulcahy Levy JM (2019) Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma. Front Oncol 9:791","journal-title":"Front Oncol"},{"key":"1212_CR37","unstructured":"Dorris K (2021) Tocilizumab in children with adamantinomatous craniopharyngioma. ClinicalTrials.gov Identifier: NCT03970226. In:. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03970226"},{"key":"1212_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","volume":"20","author":"CY Logan","year":"2004","unstructured":"Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781\u2013810","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1212_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1006\/geno.1994.1493","volume":"23","author":"C Kraus","year":"1994","unstructured":"Kraus C, Liehr T, H\u00fclsken J, Behrens J, Birchmeier W, Grzeschik KH, Ballhausen WG (1994) Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. Genomics 23:272\u2013274","journal-title":"Genomics"},{"key":"1212_CR40","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1126\/science.275.5307.1787","volume":"275","author":"PJ Morin","year":"1997","unstructured":"Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787\u20131790","journal-title":"Science"},{"key":"1212_CR41","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1126\/science.275.5307.1790","volume":"275","author":"B Rubinfeld","year":"1997","unstructured":"Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790\u20131792","journal-title":"Science"},{"key":"1212_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/73448","volume":"24","author":"S Satoh","year":"2000","unstructured":"Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y (2000) AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24:245\u2013250","journal-title":"Nat Genet"},{"key":"1212_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-010-0642-9","volume":"119","author":"A H\u00f6lsken","year":"2010","unstructured":"H\u00f6lsken A, Buchfelder M, Fahlbusch R, Bl\u00fcmcke I, Buslei R (2010) Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling. Acta Neuropathol 119:631\u2013639","journal-title":"Acta Neuropathol"},{"key":"1212_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1055\/a-0593-5956","volume":"50","author":"CEB Juc\u00e1","year":"2018","unstructured":"Juc\u00e1 CEB, Colli LM, Martins CS, Campanini ML, Paix\u00e3o B, Juc\u00e1 RV, Saggioro FP, de Oliveira RS, Moreira AC, Machado HR, Neder L, Antonini SR, de Castro M (2018) Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas. Horm Metab Res 50:575\u2013581","journal-title":"Horm Metab Res"},{"key":"1212_CR45","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2174\/138161213804581837","volume":"19","author":"A Voronkov","year":"2013","unstructured":"Voronkov A, Krauss S (2013) Wnt\/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des 19:634\u2013664","journal-title":"Curr Pharm Des"},{"key":"1212_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy N, Kurzrock R (2018) Targeting the Wnt\/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev 62:50\u201360","journal-title":"Cancer Treat Rev"},{"key":"1212_CR47","doi-asserted-by":"crossref","unstructured":"Cheltsov A, Nomura N, Yenugonda VM, Roper J, Mukthavaram R, Jiang P, Her NG, Babic I, Kesari S, Nurmemmedov E (2020) Allosteric inhibitor of \u03b2-catenin selectively targets oncogenic Wnt signaling in colon cancer. Sci Rep 10:8096-020-60784-y","DOI":"10.1038\/s41598-020-60784-y"},{"key":"1212_CR48","doi-asserted-by":"crossref","unstructured":"Lee KJ, Chang WL, Chen X, Valiyaveettil J, Ramirez-Alcantara V, Gavin E, Musiyenko A, Madeira da Silva L, Annamdevula NS, Leavesley SJ, Ward A, Mattox T, Lindsey AS, Andrews J, Zhu B, Wood C, Neese A, Nguyen A, Berry K, Maxuitenko Y, Moyer MP, Nurmemmedov E, Gorman G, Coward L, Zhou G, Keeton AB, Cooper HS, Clapper ML, Piazza GA (2021) Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic \u03b2-Catenin. Cancer Prev Res (Phila) 14:995\u20131008","DOI":"10.1158\/1940-6207.CAPR-21-0208"},{"key":"1212_CR49","doi-asserted-by":"publisher","first-page":"153303382110412","DOI":"10.1177\/15330338211041253","volume":"20","author":"J Hu","year":"2021","unstructured":"Hu J, Wang Z, Chen J, Yu Z, Zhang J, Li W, Lin M, Yang X, Liu H (2021) Overexpression of ICAT Inhibits the Progression of Colorectal Cancer by Binding with \u03b2-Catenin in the Cytoplasm. Technol Cancer Res Treat 20:15330338211041253. doi: https:\/\/doi.org\/10.1177\/15330338211041253","journal-title":"Technol Cancer Res Treat"},{"key":"1212_CR50","doi-asserted-by":"crossref","unstructured":"Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O, Koc DY, Pamir MN, Kilic T (2010) Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence.Neurosurgery66:744 \u2013 50; discussion 750","DOI":"10.1227\/01.NEU.0000367553.65099.14"},{"key":"1212_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00401-012-0957-9","volume":"124","author":"CL Andoniadou","year":"2012","unstructured":"Andoniadou CL, Gaston-Massuet C, Reddy R, Schneider RP, Blasco MA, Le Tissier P, Jacques TS, Pevny LH, Dattani MT, Martinez-Barbera JP (2012) Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol 124:259\u2013271","journal-title":"Acta Neuropathol"},{"key":"1212_CR52","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-05-0129","volume":"11","author":"E Ulfarsson","year":"2005","unstructured":"Ulfarsson E, Karstr\u00f6m A, Yin S, Girnita A, Vasilcanu D, Thoren M, Kratz G, Hillman J, Axelson M, Larsson O, Girnita L (2005) Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res 11:4674\u20134680","journal-title":"Clin Cancer Res"},{"key":"1212_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jocn.2012.04.014","volume":"20","author":"Q Li","year":"2013","unstructured":"Li Q, You C, Liu L, Rao Z, Sima X, Zhou L, Xu J (2013) Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R). J Clin Neurosci 20:153\u2013157","journal-title":"J Clin Neurosci"},{"key":"1212_CR54","doi-asserted-by":"publisher","unstructured":"Gump JM, Donson AM, Birks DK, Amani VM, Rao KK, Griesinger AM, Kleinschmidt-DeMasters BK, Johnston JM, Anderson RC, Rosenfeld A, Handler M, Gore L, Foreman N, Hankinson TC (2015) Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun 3:30\u2013015\u20130211\u20135. doi: https:\/\/doi.org\/10.1186\/s40478-015-0211-5","DOI":"10.1186\/s40478-015-0211-5"},{"key":"1212_CR55","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00701-015-2519-0","volume":"157","author":"Y Ogawa","year":"2015","unstructured":"Ogawa Y, Watanabe M, Tominaga T (2015) Prognostic factors of craniopharyngioma with special reference to autocrine\/paracrine signaling: underestimated implication of growth hormone receptor. Acta Neurochir (Wien) 157:1731\u20131740","journal-title":"Acta Neurochir (Wien)"},{"key":"1212_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.wneu.2020.02.022","volume":"138","author":"Y Ogawa","year":"2020","unstructured":"Ogawa Y, Kudo M, Watanabe M, Tominaga T (2020) Heterogeneity of Growth Hormone Receptor Expression in Craniopharyngioma-Implications for Surgical Strategy. World Neurosurg 138:89\u201392","journal-title":"World Neurosurg"},{"key":"1212_CR57","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1365-2265.2006.02508.x","volume":"64","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Warner JT, Marland A, Shine B, Ryan F, Arnold J, Turner HE, Wass JA (2006) GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 64:556\u2013560","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1212_CR58","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1365-2265.2007.03135.x","volume":"68","author":"TT Chung","year":"2008","unstructured":"Chung TT, Evanson J, Walker D, Akker SA, Besser GM, Monson JP, Grossman AB, Drake WM (2008) Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. Clin Endocrinol (Oxf) 68:965\u2013969","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1212_CR59","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1530\/EJE-12-0077","volume":"166","author":"DS Olsson","year":"2012","unstructured":"Olsson DS, Buchfelder M, Wiendieck K, Kremenevskaja N, Bengtsson B, Jakobsson KE, Jarfelt M, Johannsson G, Nilsson AG (2012) Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J Endocrinol 166:1061\u20131068","journal-title":"Eur J Endocrinol"},{"key":"1212_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","volume":"366","author":"N Normanno","year":"2006","unstructured":"Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2\u201316","journal-title":"Gene"},{"key":"1212_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-005-9011-0","volume":"95","author":"HW Lo","year":"2006","unstructured":"Lo HW, Hsu SC, Hung MC (2006) EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95:211\u2013218","journal-title":"Breast Cancer Res Treat"},{"key":"1212_CR62","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41418-020-00693-9","volume":"28","author":"EL Morgan","year":"2021","unstructured":"Morgan EL, Scarth JA, Patterson MR, Wasson CW, Hemingway GC, Barba-Moreno D, Macdonald A (2021) E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer. Cell Death Differ 28:1669\u20131687","journal-title":"Cell Death Differ"},{"key":"1212_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1634\/theoncologist.2014-0154","volume":"20","author":"M Burotto","year":"2015","unstructured":"Burotto M, Manasanch EE, Wilkerson J, Fojo T (2015) Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20:400\u2013410","journal-title":"Oncologist"},{"key":"1212_CR64","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s12325-018-0791-0","volume":"35","author":"G Fornasier","year":"2018","unstructured":"Fornasier G, Francescon S, Baldo P (2018) An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. Adv Ther 35:1497\u20131509","journal-title":"Adv Ther"},{"key":"1212_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11060-016-2273-z","volume":"131","author":"Y Wang","year":"2017","unstructured":"Wang Y, Deng J, Guo G, Tong A, Peng X, Chen H, Xu J, Liu Y, You C, Zhou L (2017) Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma. J Neurooncol 131:21\u201329","journal-title":"J Neurooncol"},{"key":"1212_CR66","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/jcm9020519","volume":"9","author":"R Whelan","year":"2020","unstructured":"Whelan R, Prince E, Gilani A, Hankinson T (2020) The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. J Clin Med 9:519. doi: https:\/\/doi.org\/10.3390\/jcm9020519","journal-title":"J Clin Med"},{"key":"1212_CR67","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00381-010-1245-4","volume":"26","author":"BL Pettorini","year":"2010","unstructured":"Pettorini BL, Inzitari R, Massimi L, Tamburrini G, Caldarelli M, Fanali C, Cabras T, Messana I, Castagnola M, Di Rocco C (2010) The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Childs Nerv Syst 26:1779\u20131784","journal-title":"Childs Nerv Syst"},{"key":"1212_CR68","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1177\/0883073810376447","volume":"25","author":"A Kumar","year":"2010","unstructured":"Kumar A, Kasliwal MK, Suri A, Sharma BS (2010) Spontaneous asymptomatic rupture of cystic craniopharyngioma in a child: case report and review of the literature. J Child Neurol 25:1555\u20131558","journal-title":"J Child Neurol"},{"key":"1212_CR69","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.3892\/mmr.2017.6538","volume":"15","author":"J Zhou","year":"2017","unstructured":"Zhou J, Zhang C, Pan J, Chen L, Qi ST (2017) Interleukin\u20136 induces an epithelial\u2013mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration. Mol Med Rep 15:4123\u20134131","journal-title":"Mol Med Rep"},{"key":"1212_CR70","first-page":"505","volume":"14","author":"M Mori","year":"2004","unstructured":"Mori M, Takeshima H, Kuratsu J (2004) Expression of interleukin-6 in human craniopharyngiomas: a possible inducer of tumor-associated inflammation. Int J Mol Med 14:505\u2013509","journal-title":"Int J Mol Med"},{"key":"1212_CR71","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.10281","volume":"94","author":"S Vidal","year":"2002","unstructured":"Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW (2002) Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer 94:738\u2013745","journal-title":"Cancer"},{"key":"1212_CR72","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/0028-3886.141232","volume":"62","author":"H Liu","year":"2014","unstructured":"Liu H, Liu Z, Li J, Li Q, You C, Xu J (2014) Relative quantitative expression of hypoxia-inducible factor 1\u03b1 messenger ribonucleic acid in recurrent craniopharyngiomas. Neurol India 62:53\u201356","journal-title":"Neurol India"},{"issue":"Suppl 1","key":"1212_CR73","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.surneu.2006.05.047","volume":"66","author":"J Xu","year":"2006","unstructured":"Xu J, Zhang S, You C, Wang X, Zhou Q (2006) Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol 66(Suppl 1):S30\u2013S34","journal-title":"Surg Neurol"},{"key":"1212_CR74","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1002\/cam4.2537","volume":"8","author":"F Yamasaki","year":"2019","unstructured":"Yamasaki F, Kolakshyapati M, Takano M, Yonezawa U, Nishibuchi I, Imano N, Taguchi A, Onishi S, Amatya VJ, Takeshima Y, Nagata Y, Kurisu K, Sugiyama K (2019) Effect of bevacizumab against cystic components of brain tumors. Cancer Med 8:6519\u20136527","journal-title":"Cancer Med"},{"key":"1212_CR75","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300\u20135309","journal-title":"Clin Cancer Res"},{"key":"1212_CR76","doi-asserted-by":"crossref","unstructured":"Ito A, Kondo S, Tada K, Kitano S (2015) Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015:605478","DOI":"10.1155\/2015\/605478"},{"key":"1212_CR77","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.3390\/cancers13184573","volume":"13","author":"C Pisibon","year":"2021","unstructured":"Pisibon C, Ouertani A, Bertolotto C, Ballotti R, Cheli Y (2021) Immune Checkpoints in Cancers: From Signaling to the Clinic. Cancers (Basel) 13:4573. doi: https:\/\/doi.org\/10.3390\/cancers13184573","journal-title":"Cancers (Basel)"},{"key":"1212_CR78","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","volume":"20","author":"S Coy","year":"2018","unstructured":"Coy S, Rashid R, Lin JR, Du Z, Donson AM, Hankinson TC, Foreman NK, Manley PE, Kieran MW, Reardon DA, Sorger PK, Santagata S (2018) Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol 20:1101\u20131112","journal-title":"Neuro Oncol"},{"key":"1212_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00381-018-3925-4","volume":"35","author":"R Borrill","year":"2019","unstructured":"Borrill R, Cheesman E, Stivaros S, Kamaly-Asl ID, Gnanalingham K, Kilday JP (2019) Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Childs Nerv Syst 35:169\u2013173","journal-title":"Childs Nerv Syst"},{"key":"1212_CR80","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2010.1.FOCUS09307","volume":"28","author":"I Yang","year":"2010","unstructured":"Yang I, Sughrue ME, Rutkowski MJ, Kaur R, Ivan ME, Aranda D, Barani IJ, Parsa AT (2010) Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus 28:E5","journal-title":"Neurosurg Focus"},{"key":"1212_CR81","unstructured":"Brastianos. Priscilla K (2021) Vemurafenib and cobimetinib in treating patients with BRAFV600E mutation positive craniopharyngioma. ClinicalTrials.gov Identifier: NCT03224767. In:. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03224767"},{"key":"1212_CR82","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0065-230X(08)60765-4","volume":"74","author":"TS Lewis","year":"1998","unstructured":"Lewis TS, Shapiro PS, Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49\u2013139","journal-title":"Adv Cancer Res"},{"key":"1212_CR83","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0248-4900(01)01125-X","volume":"93","author":"C Peyssonnaux","year":"2001","unstructured":"Peyssonnaux C, Eych\u00e8ne A (2001) The Raf\/MEK\/ERK pathway: new concepts of activation. Biol Cell 93:53\u201362","journal-title":"Biol Cell"},{"key":"1212_CR84","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954","journal-title":"Nature"},{"key":"1212_CR85","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/PAT.0b013e328360b61d","volume":"45","author":"S Pakneshan","year":"2013","unstructured":"Pakneshan S, Salajegheh A, Smith RA, Lam AK (2013) Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45:346\u2013356","journal-title":"Pathology"},{"key":"1212_CR86","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00401-014-1270-6","volume":"127","author":"SJ Larkin","year":"2014","unstructured":"Larkin SJ, Preda V, Karavitaki N, Grossman A, Ansorge O (2014) BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol 127:927\u2013929","journal-title":"Acta Neuropathol"},{"key":"1212_CR87","doi-asserted-by":"publisher","first-page":"153473542199007","DOI":"10.1177\/1534735421990078","volume":"20","author":"S Sood","year":"2021","unstructured":"Sood S, Jayachandiran R, Pandey S (2021) Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integr Cancer Ther 20:1534735421990078","journal-title":"Integr Cancer Ther"},{"key":"1212_CR88","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11864-021-00827-2","volume":"22","author":"BR Halle","year":"2021","unstructured":"Halle BR, Johnson DB (2021) Defining and Targeting BRAF Mutations in Solid Tumors. Curr Treat Options Oncol 22:30\u2013021-00827-2","journal-title":"Curr Treat Options Oncol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01212-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T04:13:53Z","timestamp":1654748033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01212-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01212-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"21 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author has no conflict of interest and financial support in relation to the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and\/or animal participants"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}